Literature DB >> 24653629

BCNU/PLGA microspheres: a promising strategy for the treatment of gliomas in mice.

Tongming Zhu1, Yiwen Shen1, Qisheng Tang1, Luping Chen1, Huasong Gao1, Jianhong Zhu1.   

Abstract

OBJECTIVE: To investigate the effects of BCNU/PLGA microspheres on tumor growth, apoptosis and chemotherapy resistance in a C57BL/6 mice orthotopic brain glioma model using GL261 cell line.
METHODS: BCNU/PLGA sustained-release microspheres were prepared by the water-in-oil-in-water emulsion technique. GL261 cells were intracranially injected into C57BL/6 mouse by using the stereotactic technology. A total of 60 tumor-bearing mice were randomly and equally divided into three groups: untreated control, PLGA treated, BCNU/PLGA treated. Magnetic resonance imaging (MRI) was taken to evaluate tumor volume. BCNU/PLGA sustained-release wafers were implanted in the treatment group two weeks after inoculation. Survival time and quality were observed. Specimens were harvested, and immunohistochemical staining was used to check the expression of Bax, Bcl-2, and O(6)-methylguanine-DNA methyltransferase (MGMT). Statistical methods was used for analysis of relevant data.
RESULTS: BCNU/PLGA sustained-release wafers were fabricated and implanted successfully. There is statistical difference of survival time between the BCNU/PLGA treated group and control groups (P<0.05). MRI scan showed inhibitory effect of BCNU/PLGA on tumor growth. Compared to the group A and B, BCNU/PLGA decreased the expression of apoptosis related gene Bcl-2 (P<0.05), but did not elevate the expression level of Bax (P>0.05), with the ratio of Bax/Bcl-2 increased. For MGMT protein expression, no statistically significant change was found in treated group (P>0.05).
CONCLUSIONS: Local implantation of BCNU/PLGA microspheres improved the survival quality and time of GL261 glioma-bearing mice significantly, inhibited the tumor proliferation, induced more cell apoptosis, and did not increase the chemotherapy resistance.

Entities:  

Keywords:  BCNU/PLGA microspheres; apoptosis; glioma; interstitial chemotherapy

Year:  2014        PMID: 24653629      PMCID: PMC3937755          DOI: 10.3978/j.issn.1000-9604.2014.02.01

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  28 in total

Review 1.  Bcl-2 proteins and mitochondria--specificity in membrane targeting for death.

Authors:  Jennefer Lindsay; Mauro Degli Esposti; Andrew P Gilmore
Journal:  Biochim Biophys Acta       Date:  2010-11-05

2.  A review of the biocompatibility of implantable devices: current challenges to overcome foreign body response.

Authors:  Yoshinori Onuki; Upkar Bhardwaj; Fotios Papadimitrakopoulos; Diane J Burgess
Journal:  J Diabetes Sci Technol       Date:  2008-11

3.  BCNU-loaded PEG-PLLA ultrafine fibers and their in vitro antitumor activity against Glioma C6 cells.

Authors:  Xiuling Xu; Xuesi Chen; Xiaoyi Xu; Tiancheng Lu; Xin Wang; Lixin Yang; Xiabin Jing
Journal:  J Control Release       Date:  2006-06-23       Impact factor: 9.776

4.  Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres.

Authors:  P Menei; V Daniel; C Montero-Menei; M Brouillard; A Pouplard-Barthelaix; J P Benoit
Journal:  Biomaterials       Date:  1993-05       Impact factor: 12.479

5.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.

Authors:  M Esteller; M Toyota; M Sanchez-Cespedes; G Capella; M A Peinado; D N Watkins; J P Issa; D Sidransky; S B Baylin; J G Herman
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

6.  Evaluation of in vitro and in vivo antitumor activity of BCNU-loaded PLGA wafer against 9L gliosarcoma.

Authors:  Jin Soo Lee; Tae Kun An; Gang Soo Chae; Je Kyo Jeong; Sun Hang Cho; Hai Bang Lee; Gilson Khang
Journal:  Eur J Pharm Biopharm       Date:  2005-01       Impact factor: 5.571

7.  O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.

Authors:  Emmanuèle Lechapt-Zalcman; Guénaëlle Levallet; Audrey Emmanuelle Dugué; Anne Vital; Marie-Danièle Diebold; Philippe Menei; Philippe Colin; Philippe Peruzzy; Evelyne Emery; Myriam Bernaudin; Françoise Chapon; Jean-Sébastien Guillamo
Journal:  Cancer       Date:  2012-02-22       Impact factor: 6.860

Review 8.  Epigenetic mechanisms in glioblastoma multiforme.

Authors:  Raman P Nagarajan; Joseph F Costello
Journal:  Semin Cancer Biol       Date:  2009-02-20       Impact factor: 15.707

9.  Three weeks release BCNU loaded hydrophilic-PLGA microspheres for interstitial chemotherapy: Development and activity against human glioblastoma cells.

Authors:  María Esther Gil-Alegre; Isabel González-Alvarez; Laura Gutiérrez-Paúls; Ana Isabel Torres-Suárez
Journal:  J Microencapsul       Date:  2008-12       Impact factor: 3.142

10.  Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.

Authors:  Umar Akbar; Terreia Jones; Jon Winestone; Madison Michael; Atul Shukla; Yichun Sun; Christopher Duntsch
Journal:  J Neurooncol       Date:  2009-04-01       Impact factor: 4.130

View more
  2 in total

1.  The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8+T Cell Anti-tumor Activity.

Authors:  Anne Kleijn; Wouter van den Bossche; Erik S Haefner; Zineb Belcaid; Chantal Burghoorn-Maas; Jenneke J Kloezeman; Suzan D Pas; Sieger Leenstra; Reno Debets; Jeroen de Vrij; Clemens M F Dirven; Martine L M Lamfers
Journal:  Mol Ther Oncolytics       Date:  2017-03-01       Impact factor: 7.200

2.  Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response: Challenges, Obstacles and Future Perspectives.

Authors:  Ana Paula Candiota; Carles Arús
Journal:  Metabolites       Date:  2022-03-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.